Advanced modeling, simulation, and quantitative decision support across the pharmaceutical development lifecycle, reducing uncertainty and improving scientific confidence.
Development Intelligence
PBPK
01
Mechanistic models that integrate physiology, drug properties, and biological processes to predict drug behavior across populations, clinical scenarios, and development stages.
Drug drug interactions, special populations, first in human predictions, pediatric extrapolation, and regulatory support.
PBBM
02
Connect formulation attributes, dissolution behavior, and gastrointestinal physiology to understand how product performance translates into in vivo outcomes.
Formulation optimization, dissolution method development, clinically relevant specifications, virtual bioequivalence, and regulatory strategy.
IVIVC / IVIVE
03
Establish quantitative relationships between experimental data and biological relevance, bridging laboratory observations with clinical decision making.
Formulation selection, development strategy, translational risk assessment, and model-informed evidence generation.
Additional Capabilities
Evaluate formulation changes, assess development risk, and support bioequivalence strategy before costly clinical studies.
Translate findings across species, formulations, and development stages to support dose selection and clinical planning.
Access an integrated ecosystem for PBPK, IVIVC, Virtual Bioequivalence, experimental design, data extraction, and quantitative decision support.
Expert guidance for regulatory interactions, development planning, model qualification, and model informed decision making.
Whether supporting formulation development, bioequivalence programs, translational research, or regulatory submissions, KinetiX turns complex scientific questions into practical development strategy.
Start a scientific conversation